The U.S. Food and Drug Administration (FDA) has approved nerandomilast, an oral medication developed by Boehringer Ingelheim, to treat adults with idiopathic pulmonary fibrosis (IPF) — when the lung disease has no known cause. The therapy will be marketed under the brand name Jascayd. According to a press release from the FDA, the decision marks […] The post FDA approves Jascayd as first new IPF treatment in over 10 years appeared first on Pulmonary Fibrosis News.| Pulmonary Fibrosis News – The Web's Daily Resource for PF News